ClinicalTrials.gg
RecruitingNCT06863272Updated Oct 9, 2026

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

A Phase 1/2 interventional study of Docetaxel and Ifinatamab Deruxtecan in Castration-Resistant Prostatic Cancer and Metastasis, sponsored by Merck Sharp & Dohme LLC. Recruiting at 82 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 9, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Planned enrollment
6th of 42
360 · median 91
Started
2025
with 3 others
Phase 1/2
8 of 50
5 open now
Primary completion
2031-10
later than 22 of 22 live
Registered
42nd of 50
by date
Lead sponsor
2 of 50
Merck Sharp & Dohme LLC

Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 6th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 22 of the 22 other live ones, and was the 42nd registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:

  • The safety of the study treatment and if people tolerate it.
  • A safe dose level of I-DXd that can be used with other treatments.
  • Participant levels of prostate specific antigen (PSA) during treatment.
Read the detailed description

This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).

The master screening protocol is MK-2400-U01

03

Conditions studied

  • Castration-Resistant Prostatic Cancer
  • Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has - or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
  • Has current evidence of distant disease
  • Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
  • Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
  • An (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
  • Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • Uncontrolled or significant cardiovascular disease
  • History of pituitary dysfunction
  • Poorly controlled diabetes mellitus
  • History or current condition of adrenal insufficiency (eg, Addison's disease)
  • Has received prior treatment with taxane-based chemotherapy agent for castration-resistant prostate cancer (mCRPC).
  • Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/), topical steroids (for mild skin conditions), or intra-articular steroid injections
  • Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active disease that has required systemic treatment in the past 2 years
  • History of allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    Docetaxel

    Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days.

    Drug: Docetaxel

  • Experimental
    Ifinatamab Deruxtecan (I-DXd)

    Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent.

    Drug: Ifinatamab Deruxtecan · Drug: Rescue Medication

  • Experimental
    I-DXd + Opevesostat

    Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met.

    Drug: Ifinatamab Deruxtecan · Drug: Opevesostat · Drug: Rescue Medication

  • Experimental
    I-DXd +ARPI (Abiraterone or Enzalutamide)

    Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met.

    Drug: Ifinatamab Deruxtecan · Drug: Abiraterone · Drug: Enzalutamide · Drug: Rescue Medication

Interventions

  • Administered via Intravenous (IV) infusion at a specified dose on specified days

  • Administered via IV infusion at a specified dose on specified days

    Also known as: I-DXd, MK-2400, DS-7300a

  • Administered orally at a specified dose on specified days

    Also known as: MK-5684, ODM-208

  • Administered orally at a specified dose on specified days

  • Administered orally at a specified dose on specified days

  • DrugRescue Medication

    Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label.

06

What researchers measure

Primary outcomes

  1. Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only

    The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for \>1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (\>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing \>25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity.

    Time frame: Up to approximately 21 days

  2. Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 54 months

  3. Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 24 months

  4. Efficacy Phase: Prostate-Specific Antigen (PSA) response rate

    PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart.

    Time frame: Up to approximately 54 months

  5. Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only

    The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for \>1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (\>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing \>25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity.

    Time frame: Up to approximately 21 days

  6. Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 21 days

  7. Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 21 days

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 54 months

  2. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (\>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm

    Time frame: Up to approximately 54 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves.

    Time frame: Up to approximately 54 months

  4. Duration of Response (DOR)

    DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm.

    Time frame: Up to approximately 54 months

  5. Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)

    TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm.

    Time frame: Up to approximately 54 months

  6. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1\) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.

    Time frame: Up to approximately 54 months

  7. Time to pain progression (TTPP)

    The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score.

    Time frame: Up to approximately 54 months

07

Study locations

80 of 82 sites recruiting
  • UCLA Hematology & Oncology ( Site 0003)
    Los Angeles, California 90095, United States
    Recruiting
    • Study Coordinator · Contact310-829-5471
  • University of California-Irvine Medical Center ( Site 0016)
    Orange, California 92868, United States
    Recruiting
    • Study Coordinator · Contact714-456-5153
  • UCSF Medical Center at Mission Bay ( Site 0034)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-502-2097
  • MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Study Coordinator · Contact202-877-3061
  • University of Michigan ( Site 0021)
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Study Coordinator · Contact734-936-4000
  • Memorial Sloan Kettering Cancer Center ( Site 0006)
    New York, New York 10065, United States
    Recruiting
    • Study Coordinator · Contact347-798-8620
  • UPMC Hillman Cancer Center ( Site 0014)
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Study Coordinator · Contact412-647-2811
  • The West Clinic, PLLC dba West Cancer Center ( Site 0005)
    Germantown, Tennessee 38138, United States
    Recruiting
    • Study Coordinator · Contact901-683-0055
  • Fred Hutchinson Cancer Center ( Site 0013)
    Seattle, Washington 98109, United States
    Recruiting
    • Study Coordinator · Contact206-288-1111
  • Instituto Alexander Fleming ( Site 0202)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact5411 3221 8900
  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
    La Rioja, F5300COE, Argentina
    Recruiting
    • Study Coordinator · Contact54-380-443-6443
  • Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
    Macquarie University, New South Wales 2109, Australia
    Recruiting
    • Study Coordinator · Contact+61 2 9812 2956
  • Liga Norte Riograndense Contra o Câncer ( Site 0271)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact(84) 4009-5595
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
    Recruiting
    • Study Coordinator · Contact+555132148151
  • Hospital Moinhos de Vento ( Site 0278)
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
    Recruiting
    • Study Coordinator · Contact+55 51 3314-3209
  • Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
    Bragança Paulista, São Paulo 12916-542, Brazil
    Recruiting
    • Study Coordinator · Contact+551124901366
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
    Ribeirão Preto, São Paulo 14048900, Brazil
    Recruiting
    • Study Coordinator · Contact(16) 3963-6487
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Study Coordinator · Contact+55 17 99625-3919
  • Hospital Alemao Oswaldo Cruz ( Site 0279)
    São Paulo, São Paulo 01327-001, Brazil
    Recruiting
    • Study Coordinator · Contact55 11 3549-0009
  • IPITEC ( Site 0275)
    São Paulo, 01221-020, Brazil
    Recruiting
    • Study Coordinator · Contact+551194322-6006
  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
    São Paulo, 03102-006, Brazil
    Recruiting
    • Study Coordinator · Contact+551144500360
  • BC Cancer - Vancouver Center ( Site 0103)
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
    • Study Coordinator · Contact6048776000
  • Sunnybrook Research Institute ( Site 0109)
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Study Coordinator · Contact4164806100
  • Princess Margaret Cancer Centre ( Site 0102)
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Study Coordinator · Contact4169464501
  • Jewish General Hospital ( Site 0108)
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
    • Study Coordinator · Contact5143408110
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
    • Study Coordinator · Contact8197802222
  • Clinica Universidad Catolica del Maule ( Site 0236)
    Talca, Maule Region 3465584, Chile
    Recruiting
    • Study Coordinator · Contact56992992913
  • Fundación Arturo López Pérez ( Site 0232)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Centro de Oncología de Precisión ( Site 0241)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact+56225189885
  • Bradfordhill ( Site 0231)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • ONCOCENTRO APYS ( Site 0234)
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Study Coordinator · Contact+56323320850
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
    Bordeaux, Gironde 33000, France
    Recruiting
    • Study Coordinator · Contact+33556333261
  • Centre Oscar Lambret ( Site 0495)
    Lille, Nord 59000, France
    Recruiting
    • Study Coordinator · Contact+333 20 29 56 06
  • Institut De Cancerologie De L Ouest ( Site 0494)
    Saint-Herblain, Pays de la Loire Region 44800, France
    Recruiting
    • Study Coordinator · Contact+33240679900
  • Centre Hospitalier de la Cote Basque ( Site 0496)
    Bayonne, Pyrenees-Atlantiques 64100, France
    Recruiting
    • Study Coordinator · Contact+33559443762
  • centre hospitalier lyon sud ( Site 0497)
    Pierre-Bénite, Rhone 69310, France
    Recruiting
    • Study Coordinator · Contact33 4 78 86 43 24
  • NCT ( Site 0528)
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Study Coordinator · Contact00496221566857
  • Universitaetsklinikum Ulm. ( Site 0530)
    Ulm, Baden-Wurttemberg 89081, Germany
    Recruiting
    • Study Coordinator · Contact+4973150058188
  • Universitaetsklinikum Jena ( Site 0525)
    Jena, Thuringia 07747, Germany
    Recruiting
    • Study Coordinator · Contact+49-3641-9-329901
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
    Hamburg, 20246, Germany
    Recruiting
    • Study Coordinator · Contact+4915222815585
  • St Vincent's University Hospital ( Site 0463)
    Dublin, Dublin D04 T6F4, Ireland
    Recruiting
    • Study Coordinator · Contact+353 1 221 4982
  • Beaumont Hospital, Dublin ( Site 0465)
    Dublin, D09 V2N0, Ireland
    Recruiting
    • Study Coordinator · Contact0035318092010
  • Tallaght University Hospital ( Site 0462)
    Dublin, D24 NR0A, Ireland
    Recruiting
    • Study Coordinator · Contact0035314144209
  • Rambam Health Care Campus ( Site 0400)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact972(47776234)
  • Hadassah Medical Center ( Site 0404)
    Jerusalem, 9112001, Israel
    Recruiting
    • Study Coordinator · Contact+97226777333
  • Rabin Medical Center ( Site 0402)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+972544594048
  • Sheba Medical Center ( Site 0401)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+97235303030
  • Sourasky Medical Center ( Site 0403)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact+97236947832
  • AOU San Luigi Gonzaga di Orbassano ( Site 0434)
    Orbassano, Torino 10143, Italy
    Recruiting
    • Study Coordinator · Contact00390119026534
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
    Brescia, 25123, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
    Milan, 20133, Italy
    Recruiting
    • Study Coordinator · Contact+390223904449
  • A.O.U. Federico II di Napoli ( Site 0435)
    Naples, 80131, Italy
    Recruiting
    • Study Coordinator · Contact+390817463660
  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact+390630155202
  • Ziekenhuis Gelderse Vallei ( Site 0683)
    Ede, Gelderland 6716 RP, Netherlands
    Recruiting
    • Study Coordinator · Contact+31 318 435499
  • UMC St. Radboud ( Site 0679)
    Nijmegen, Gelderland 6525 GA, Netherlands
    Recruiting
    • Study Coordinator · Contact+31 24 361 1111
  • Nij Smellinghe ( Site 0684)
    Drachten, Provincie Friesland 9202 NN, Netherlands
    Recruiting
    • Study Coordinator · Contact0512 588 888
  • Auckland City Hospital ( Site 0831)
    Auckland, 1023, New Zealand
    Recruiting
    • Study Coordinator · Contact+6493074949
  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
    Poznan, Greater Poland Voivodeship 60-355, Poland
    Recruiting
    • Study Coordinator · Contact+61 854 79 87
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48 22 546 33 81
  • Uniwersyteckie Centrum Kliniczne ( Site 0588)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
    • Study Coordinator · Contact+48 58 584 44 66
  • Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Recruiting
    • Study Coordinator · Contact+48943488930
  • Asan Medical Center ( Site 0925)
    Songpagu, Seoul 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230105977
  • Severance Hospital Yonsei University Health System ( Site 0924)
    Seoul, 03722, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Samsung Medical Center ( Site 0926)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234103459
  • ICO L Hospitalet ( Site 0617)
    L Hospitalet Del Llobregat, Barcelona 08908, Spain
    Recruiting
    • Study Coordinator · Contact+34932607744
  • Hospital Universitario Ramon y Cajal ( Site 0620)
    Madrid, 28034, Spain
    Recruiting
    • Study Coordinator · Contact+34913368263
  • Hospital Clinico San Carlos ( Site 0618)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34913303546
  • Hospital Universitario 12 de Octubre ( Site 0622)
    Madrid, 28041, Spain
    Recruiting
    • Study Coordinator · Contact+34608464547
  • Hospital Universitario Virgen del Rocio ( Site 0619)
    Seville, 41013, Spain
    Recruiting
    • Study Coordinator · Contact+34955013068
  • Taichung Veterans General Hospital ( Site 0902)
    Taichung, 40705, Taiwan
    Recruiting
    • Study Coordinator · Contact+886423592525
  • Taipei Veterans General Hospital ( Site 0901)
    Taipei, 11217, Taiwan
    Recruiting
    • Study Coordinator · Contact+886228712121
  • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
    Adana, 01250, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903223271274
  • Hacettepe Universitesi Tip Fakultesi ( Site 0648)
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 312 305 50 00
  • Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
    Ankara, 06620, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903122126040
  • Ankara Bilkent Şehir Hastanesi ( Site 0654)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903125526000
  • Koç Üniversitesi Hastanesi ( Site 0656)
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905369410661
  • Istanbul Universitesi Cerrahpasa ( Site 0649)
    Istanbul, 34098, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+902124143000
  • Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
    Rize, 53020, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+904642130491
  • Addenbrooke's Hospital ( Site 0747)
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
    Recruiting
    • Study Coordinator · Contact00441223216083
  • St Bartholomew's Hospital ( Site 0749)
    London, London, City of EC1A 7BE, United Kingdom
    Recruiting
    • Study Coordinator · Contact00442073777000
  • Royal Free Hospital ( Site 0743)
    London, London, City of NW3 2QG, United Kingdom
    Recruiting
    • Study Coordinator · Contact00442077940500/2237
  • Royal Marsden Hospital (Sutton) ( Site 0741)
    London, Surrey SM3 5PT, United Kingdom
    Recruiting
    • Study Coordinator · Contact0203 437 3500
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Oct 2031, 74 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2031 → Oct 2031 and completion Apr 2031 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 7, 2025
StartActual
Jul 3, 2025
Primary completionEst.
Oct 1, 2031was Apr 2031
CompletionEst.
Oct 1, 2031was Apr 2031
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fundación Arturo López Pérez ( Site 0232) · Santiago, Chile
Show 1 removed
  • FALP ( Site 0232) · Santiago, Chile
Oct 6, 2026
Primary completion
Apr 1, 2031→Oct 1, 2031
Oct 9, 2026
Study completion
Apr 1, 2031→Oct 1, 2031
Oct 9, 2026
Show all 2 updates
  1. Oct 9, 2026
    Primary completion Apr 1, 2031→Oct 1, 2031
    Study completion Apr 1, 2031→Oct 1, 2031
  2. Oct 6, 2026
    1 site added, 1 site removed
    Show site
    • Fundación Arturo López Pérez ( Site 0232) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0232) · Santiago, Chile
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06863272
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Jul 3, 2025
Primary completion
Oct 1, 2031 (estimated)
Completion
Oct 1, 2031 (estimated)
Last update
Oct 9, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifinatamab deruxtecan

Start the discussion